Evidence map›Paper›PMID 35857146›Full record

ArticleArchives of virology2022

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.

A V Gracheva, E R Korchevaya, Yu I Ammour, D I Smirnova, O S Sokolova, G S Glukhov, A V Moiseenko, I V Zubarev, R V Samoilikov, I A Leneva and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Archives of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

A V GrachevaI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
E R KorchevayaI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
Yu I AmmourI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
D I SmirnovaI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
O S SokolovaFaculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
G S GlukhovFaculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
A V MoiseenkoFaculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
I V ZubarevFaculty of Medicine, Lomonosov Moscow State University, Moscow, 119991, Russia.
R V SamoilikovI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
I A LenevaI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
O A SvitichI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
V V ZverevI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia.
Evgeny B FaizuloevI.I. Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064, Russia. faizuloev@mail.ru.
Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences · RULomonosov Moscow State University · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination against COVID-19 is the most effective method of controlling the spread of SARS-CoV-2 and reducing mortality from this disease. The development of vaccines with high protective activity against a wide range of SARS-CoV-2 antigenic variants remains relevant. In this regard, evaluation of the effectiveness of physical methods of virus inactivation, such as ultraviolet irradiation (UV) of the virus stock, remains relevant. This study demonstrates that the UV treatment of SARS-CoV-2 completely inactivates its infectivity while preserving its morphology, antigenic properties, and ability to induce the production of virus-neutralizing antibodies in mice through immunization. Thus, the UV inactivation of SARS-CoV-2 makes it possible to obtain viral material similar in its antigenic and immunogenic properties to the native antigen, which can be used both for the development of diagnostic test systems and for the development of an inactivated vaccine against COVID-19.

Indexed as

COVID-19Viral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesHumansMiceSARS-CoV-2Spike Glycoprotein, CoronavirusUltraviolet RaysVaccines, InactivatedAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, InactivatedViral Vaccines

Identifiers

PMID35857146
PMCPMC9296761
OpenAlexW4285891468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.